My ePortfolio Register   
 

Abstract | Full HTML Article | PDF | Portuguese ecancer 10 681 / https://doi.org/10.3332/ecancer.2016.681

Policy

Phosphoethanolamine and the danger of unproven drugs

The use of unproven forms of therapy in cancer treatment is very common. In Brazil, the distribution by researchers to patients of an investigational agent called phophoethanolamine (PHOS) has led to a widely publicized scientific scandal. PHOS is a precursor to components of the cell membrane, with some published pre-clinical studies suggesting cytotoxic activity in cancer cells. The willingness of courts and of legislators to guarantee access to PHOS in spite of the lack of any clinical data and against the recommendations of scientific and medical organisations underscores the risks that unproven agents pose to regulatory authorities, health care systems and patients, and bears resemblance to other cases such as the controversy surrounding the approval of zidovudine for AIDS treatment by the FDA.

Keywords: phosphoethanolamine, cancer, science, Brazil, ethics

Loading Article Metrics ... Please wait

Related articles

Conference Report: United against cancer: prevention to end-of-life care—highlights from the Uganda Cancer Institute–Palliative Care Association of Uganda Joint International Conference on Cancer and Palliative Care and the 7th Palliative Care Conference, 24–25 August 2017,

Abstract | Full Article | PDF Published: 14 Dec 2017 / https://doi.org/10.3332/ecancer.2017.790

Case Report: Primary non-Hodgkin lymphoma of the prostate: a case report

Abstract | Full Article | PDF Published: 12 Dec 2017 / https://doi.org/10.3332/ecancer.2017.789

Special Issue: History of the development of radiotherapy in Latin America

Abstract | Full Article | PDF Published: 30 Nov 2017 / https://doi.org/10.3332/ecancer.2017.784

Special Issue: Do we need regional guidelines for breast cancer management in the MENA region? MENA Breast Cancer Guidelines project

Abstract | Full Article | PDF Published: 30 Nov 2017 / https://doi.org/10.3332/ecancer.2017.783

Clinical Study: Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents

Abstract | Full Article | PDF Published: 23 Nov 2017 / https://doi.org/10.3332/ecancer.2017.781



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence